Published in Lancet on March 06, 2004
Clinical Importance of Glucose Regulation in Relapsing MS | NCT03004079
Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet (2012) 7.89
Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ (2006) 5.05
Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet (2012) 4.66
Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature (2012) 4.04
Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol (2008) 3.98
Good clinical outcome after ischemic stroke with successful revascularization is time-dependent. Neurology (2009) 3.45
Efficacy of site-independent telemedicine in the STRokE DOC trial: a randomised, blinded, prospective study. Lancet Neurol (2008) 3.18
Association between ICU admission during morning rounds and mortality. Chest (2009) 2.98
Methodology of the Interventional Management of Stroke III Trial. Int J Stroke (2008) 2.88
Reducing door-to-needle times using Toyota's lean manufacturing principles and value stream analysis. Stroke (2012) 2.43
The safety and efficacy of thrombolysis for strokes after cardiac catheterization. J Am Coll Cardiol (2008) 2.38
Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ (2005) 2.36
Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol (2012) 2.24
Standardized prehospital treatment of stroke. Dtsch Arztebl Int (2011) 2.21
Refining the definition of the malignant profile: insights from the DEFUSE-EPITHET pooled data set. Stroke (2011) 2.03
Correlation of cavitation with ultrasound enhancement of thrombolysis. Ultrasound Med Biol (2006) 2.00
A multilevel intervention to increase community hospital use of alteplase for acute stroke (INSTINCT): a cluster-randomised controlled trial. Lancet Neurol (2012) 1.95
Factors affecting the apparent efficacy and safety of tissue plasminogen activator in thrombotic occlusion models of stroke: systematic review and meta-analysis. J Cereb Blood Flow Metab (2010) 1.89
Imaging of the brain in acute ischaemic stroke: comparison of computed tomography and magnetic resonance diffusion-weighted imaging. J Neurol Neurosurg Psychiatry (2005) 1.86
Therapeutic hypothermia for acute ischemic stroke: ready to start large randomized trials? J Cereb Blood Flow Metab (2010) 1.85
Third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke. Trials (2008) 1.79
Equipoise among recanalization strategies. Neurology (2010) 1.77
Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev (2014) 1.76
Evaluation of the clinical-diffusion and perfusion-diffusion mismatch models in DEFUSE. Stroke (2007) 1.72
Pretreatment diffusion- and perfusion-MR lesion volumes have a crucial influence on clinical response to stroke thrombolysis. J Cereb Blood Flow Metab (2010) 1.68
Unsuspected coagulopathy rarely prevents IV thrombolysis in acute ischemic stroke. Neurology (2009) 1.59
The HAT Score: a simple grading scale for predicting hemorrhage after thrombolysis. Neurology (2008) 1.58
Design and rationale of the Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE) Trial. Int J Stroke (2012) 1.55
Validation of in vivo magnetic resonance imaging blood-brain barrier permeability measurements by comparison with gold standard histology. Stroke (2011) 1.53
Stem cells for ischemic brain injury: a critical review. J Comp Neurol (2009) 1.53
Manual aspiration thrombectomy through balloon-tipped guide catheter for rapid clot burden reduction in endovascular therapy for ICA L/T occlusion. Neuroradiology (2012) 1.49
Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke (2009) 1.44
An ethical hierarchy for decision making during medical emergencies. Ann Neurol (2010) 1.43
Multiparametric MRI and CT models of infarct core and favorable penumbral imaging patterns in acute ischemic stroke. Stroke (2012) 1.43
Improving the outcome of stroke. BMJ (2007) 1.38
Intravenous thrombolysis in acute ischaemic stroke: from trial exclusion criteria to clinical contraindications. An international Delphi study. J Neurol Neurosurg Psychiatry (2007) 1.36
Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke (2007) 1.29
Cerebral microbleeds: a review of clinical, genetic, and neuroimaging associations. Front Neurol (2014) 1.27
Thrombolytic therapy for patients who wake-up with stroke. Stroke (2009) 1.23
Evolution of the thrombolytic treatment window for acute ischemic stroke. Curr Neurol Neurosci Rep (2010) 1.21
Microbubbles improve sonothrombolysis in vitro and decrease hemorrhage in vivo in a rabbit stroke model. Invest Radiol (2011) 1.21
Stroke awareness in the general population: knowledge of stroke risk factors and warning signs in older adults. BMC Geriatr (2009) 1.21
Accelerated care versus standard care among patients with hip fracture: the HIP ATTACK pilot trial. CMAJ (2013) 1.20
Trends in thrombolytic use for ischemic stroke in the United States. J Hosp Med (2010) 1.19
The MRA-DWI mismatch identifies patients with stroke who are likely to benefit from reperfusion. Stroke (2008) 1.18
The neuroprotective effect of prostaglandin E2 EP1 receptor inhibition has a wide therapeutic window, is sustained in time and is not sexually dimorphic. J Cereb Blood Flow Metab (2008) 1.17
Remote supervision of IV-tPA for acute ischemic stroke by telemedicine or telephone before transfer to a regional stroke center is feasible and safe. Stroke (2009) 1.15
Hemorrhagic transformation of ischemic stroke in diabetics on sulfonylureas. Ann Neurol (2012) 1.14
Imaging-based treatment selection for intravenous and intra-arterial stroke therapies: a comprehensive review. Expert Rev Cardiovasc Ther (2011) 1.14
Growth of regional acute stroke systems of care in the United States in the first decade of the 21st century. Stroke (2012) 1.11
Thrombolytic therapy for acute ischaemic stroke in octogenarians: selection by magnetic resonance imaging improves safety but does not improve outcome. J Neurol Neurosurg Psychiatry (2006) 1.09
Oxygen therapy reduces secondary hemorrhage after thrombolysis in thromboembolic cerebral ischemia. J Cereb Blood Flow Metab (2010) 1.07
Validation of the use of the ROSIER scale in prehospital assessment of stroke. Ann Indian Acad Neurol (2012) 1.07
The Basilar Artery International Cooperation Study (BASICS): study protocol for a randomised controlled trial. Trials (2013) 1.06
Graphic reanalysis of the two NINDS-tPA trials confirms substantial treatment benefit. Stroke (2010) 1.05
Delay in presentation after an acute stroke in a multiethnic population in South london: the South london stroke register. J Am Heart Assoc (2012) 1.02
Expansion of recruitment time window in antihypertensive treatment of acute cerebral hemorrhage (ATACH) II trial. J Vasc Interv Neurol (2012) 1.02
The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke. BMC Neurol (2014) 1.02
The evolution of transcranial laser therapy for acute ischemic stroke, including a pooled analysis of NEST-1 and NEST-2. Curr Cardiol Rep (2010) 1.00
Delayed matrix metalloproteinase inhibition reduces intracerebral hemorrhage after embolic stroke in rats. Exp Neurol (2008) 1.00
Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence. J Cereb Blood Flow Metab (2011) 0.99
Cost-effectiveness analysis of mechanical thrombectomy in acute ischemic stroke. J Neurosurg (2009) 0.98
Safety and efficacy of alteplase in the treatment of acute ischemic stroke. Vasc Health Risk Manag (2009) 0.98
Multivariate dynamic prediction of ischemic infarction and tissue salvage as a function of time and degree of recanalization. J Cereb Blood Flow Metab (2015) 0.98
Cost-effectiveness of multimodal CT for evaluating acute stroke. Neurology (2010) 0.97
Intravenous Thrombolysis in Expanded Time Window (3-4.5 hours) in General Practice with Concurrent Availability of Endovascular Treatment. J Vasc Interv Neurol (2012) 0.97
Should the Window for Intravenous Administration of Tissue Plasminogen Activator in the Treatment of Acute Ischemic Stroke be Extended to 4.5 Hours? Can J Hosp Pharm (2009) 0.97
Management of ischaemic stroke in the acute setting: review of the current status. Cardiovasc J Afr (2013) 0.97
Proton-sensitive cation channels and ion exchangers in ischemic brain injury: new therapeutic targets for stroke? Prog Neurobiol (2014) 0.96
Extending acute trials to remote populations: a pilot study during interhospital helicopter transfer. Stroke (2009) 0.96
Tissue-type plasminogen activator as a therapeutic target in stroke. Expert Opin Ther Targets (2008) 0.95
The rise of cell therapy trials for stroke: review of published and registered studies. Stem Cells Dev (2013) 0.95
Multi-center prediction of hemorrhagic transformation in acute ischemic stroke using permeability imaging features. Magn Reson Imaging (2013) 0.94
Expansion of U.S. emergency medical service routing for stroke care: 2000-2010. West J Emerg Med (2014) 0.94
Physical activity in the prevention and treatment of stroke. ISRN Neurol (2011) 0.94
Proteomic Protease Substrate Profiling of tPA Treatment in Acute Ischemic Stroke Patients: A Step Toward Individualizing Thrombolytic Therapy at the Bedside. Transl Stroke Res (2010) 0.94
Pathophysiology of ischaemic stroke: insights from imaging, and implications for therapy and drug discovery. Br J Pharmacol (2007) 0.94
Validity and reliability of a korean version of the national institutes of health stroke scale. J Clin Neurol (2012) 0.94
A user's guide to the NINDS rt-PA stroke trial database. PLoS Med (2008) 0.93
Comparison of susceptibility weighted imaging and TOF-angiography for the detection of Thrombi in acute stroke. PLoS One (2013) 0.93
Intravenous thrombolysis for acute cerebral ischaemia in old stroke patients ≥ 80 years of age. J Neurol (2011) 0.93
Tissue plasminogen activator treatment of stroke in type-1 diabetes rats. Neuroscience (2012) 0.93
Reperfusion half-life: a novel pharmacodynamic measure of thrombolytic activity. Stroke (2008) 0.93
Awareness of necessity to call 9-1-1 for stroke symptoms, upstate New York. Prev Chronic Dis (2008) 0.92
Intra-hospital delays in stroke patients treated with rt-PA: impact of preadmission notification. J Neurol (2012) 0.91
Chrysophanol inhibits NALP3 inflammasome activation and ameliorates cerebral ischemia/reperfusion in mice. Mediators Inflamm (2014) 0.91
Differential recovery of multimodal MRI and behavior after transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab (2006) 0.91
Helicopter EMS: Research Endpoints and Potential Benefits. Emerg Med Int (2011) 0.91
Efficacy and safety of stem cell therapies for patients with stroke: a systematic review and single arm meta-analysis. Int J Stem Cells (2014) 0.91
Intravenous thrombolysis guided by a telemedicine consultation system for acute ischaemic stroke patients in China: the protocol of a multicentre historically controlled study. BMJ Open (2015) 0.90
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med (2008) 28.42
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med (2015) 18.66
Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med (2013) 14.78
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet (2010) 12.21
Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet (2007) 10.74
Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol (2006) 10.51
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med (2014) 9.33
Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med (2005) 7.92
Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med (2008) 7.25
Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial. Lancet (2015) 7.16
Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med (2015) 6.96
National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke (2006) 6.94
Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2010) 6.93
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med (2013) 6.01
NXY-059 for acute ischemic stroke. N Engl J Med (2006) 5.32
Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med (2004) 5.32
Recommendations for comprehensive stroke centers: a consensus statement from the Brain Attack Coalition. Stroke (2005) 5.18
The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke (2004) 4.39
Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. Circ Res (2003) 4.29
Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation (2006) 4.21
Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association. Stroke (2003) 4.13
Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol (2008) 3.98
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med (2012) 3.81
NXY-059 for the treatment of acute ischemic stroke. N Engl J Med (2007) 3.70
Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. Stroke (2005) 3.67
Age at stroke: temporal trends in stroke incidence in a large, biracial population. Neurology (2012) 3.62
An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2013) 3.60
Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol (2003) 3.54
Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA (2004) 3.51
Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. Stroke (2002) 3.43
National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke (2008) 3.40
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A (2009) 3.39
Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke: the Helsinki young stroke registry. Stroke (2009) 3.39
Designing a message for public education regarding stroke: does FAST capture enough stroke? Stroke (2007) 3.34
Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. Stroke (2008) 3.21
Very early administration of progesterone for acute traumatic brain injury. N Engl J Med (2014) 3.20
Incidence and short-term prognosis of transient ischemic attack in a population-based study. Stroke (2005) 3.00
A genome-wide genotyping study in patients with ischaemic stroke: initial analysis and data release. Lancet Neurol (2007) 2.99
Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke (2004) 2.97
Prognosis and safety of anticoagulation in intracranial artery dissections in adults. Stroke (2007) 2.95
Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology (2012) 2.91
Methodology of the Interventional Management of Stroke III Trial. Int J Stroke (2008) 2.88
ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med (2006) 2.86
National Stroke Association guidelines for the management of transient ischemic attacks. Ann Neurol (2006) 2.82
Thrombolysis of basilar artery occlusion: impact of baseline ischemia and time. Ann Neurol (2013) 2.77
A review of the evidence for the use of telemedicine within stroke systems of care: a scientific statement from the American Heart Association/American Stroke Association. Stroke (2009) 2.74
Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation (2002) 2.71
Gliosis and brain remodeling after treatment of stroke in rats with marrow stromal cells. Glia (2005) 2.68
Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice. J Cereb Blood Flow Metab (2005) 2.65
Stroke symptoms and the decision to call for an ambulance. Stroke (2007) 2.65
Intravenous bone marrow stromal cell therapy reduces apoptosis and promotes endogenous cell proliferation after stroke in female rat. J Neurosci Res (2003) 2.61
Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease. Am J Hum Genet (2009) 2.50
Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. Stroke (2013) 2.50
Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther (2007) 2.44
The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke (2006) 2.43
Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst (2004) 2.41
Trends in community knowledge of the warning signs and risk factors for stroke. JAMA (2003) 2.40
NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke (2008) 2.39
Comparison of 30-day mortality models for profiling hospital performance in acute ischemic stroke with vs without adjustment for stroke severity. JAMA (2012) 2.38
Perimesencephalic subarachnoid hemorrhage: incidence, risk factors, and outcome. J Stroke Cerebrovasc Dis (2007) 2.36
A test for detecting long-term sensorimotor dysfunction in the mouse after focal cerebral ischemia. J Neurosci Methods (2002) 2.35
Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol (2010) 2.31
Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke (ICTuS-L): final results. Stroke (2010) 2.29
Revascularization end points in stroke interventional trials: recanalization versus reperfusion in IMS-I. Stroke (2005) 2.26
Recommendations for the implementation of telemedicine within stroke systems of care: a policy statement from the American Heart Association. Stroke (2009) 2.26
Individual patient data subgroup meta-analysis of surgery for spontaneous supratentorial intracerebral hemorrhage. Stroke (2012) 2.26
Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke (2002) 2.24
Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study. J Cereb Blood Flow Metab (2006) 2.20
Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology (2002) 2.18
Treatment of traumatic brain injury in adult rats with intravenous administration of human bone marrow stromal cells. Neurosurgery (2003) 2.16
Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis (2012) 2.15
Houston paramedic and emergency stroke treatment and outcomes study (HoPSTO). Stroke (2005) 2.12
Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2011) 2.12
Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol (2005) 2.11
Therapeutic benefit of bone marrow stromal cells administered 1 month after stroke. J Cereb Blood Flow Metab (2006) 2.10
Intracranial hemorrhage associated with revascularization therapies. Stroke (2007) 2.08
Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison. Appl Health Econ Health Policy (2012) 2.06
Hematoma resolution as a target for intracerebral hemorrhage treatment: role for peroxisome proliferator-activated receptor gamma in microglia/macrophages. Ann Neurol (2007) 2.05